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A B S T R A C T
Oxysterols are oxygenated forms of cholesterol or its precursors. They are formed enzymatically and via
reactive oxygen species. Oxysterols are intermediates in bile acid and steroid hormone biosynthetic
pathways and are also bioactive molecules in their own right, being ligands to nuclear receptors and also
regulators of the processing of steroid regulatory element-binding proteins (SREBPs) to their active forms
as transcription factors regulating cholesterol and fatty acid biosynthesis. Oxysterols are implicated in
the pathogenesis of multiple disease states ranging from atherosclerosis and cancer to multiple sclerosis
and other neurodegenerative diseases including Alzheimer’s and Parkinson’s disease. Analysis of
oxysterols is challenging on account of their low abundance in biological systems in comparison to
cholesterol, and due to the propensity of cholesterol to undergo oxidation in air to generate oxysterols
with the same structures as those present endogenously. In this article we review the mass spectrometry-
based methods for oxysterol analysis paying particular attention to analysis by liquid chromatography–
mass spectrometry (LC–MS).
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Cholesterol is the archetypical sterol, being an essential
component of cell membranes throughout the animal kingdom
[1]. The ﬁrst step of cholesterol metabolism is oxidation to an
oxysterol [2]. Similarly, precursors of cholesterol can be oxidised to
oxysterols [3]. Consequently, oxysterols are a large family of
molecules where cholesterol or its precursors have additional
oxygen functionalities at one or more positions in the ring system
or on the side-chain. Oxysterol analysis dates back to the 1940s and
even at that time the potential of cholesterol to undergo
nonenzymatic oxidation ex vivo was noted [4]. This can be
problematic as cholesterol can be oxidised in air to give identical
products to some of those formed enzymatically. Throughout the
years, from the 1940s onwards, there have been many reports
where oxysterols formed by nonenzymatic autoxidation ex vivo
have been confused by those formed enzymatically in vivo [2]. The
situation is further complicated by the fact that oxysterols can be
formed endogenously by reactive oxygen species (ROS) [5,6] with
the same structures as those formed ex vivo or enzymatically e.g. 7-
oxocholesterol (7-OC), 7b-hydroxycholesterol (7b-HC) [7,8]. Oxy-
sterols are key members of the bile acid and steroid hormone
biosynthesis pathways [9]. Mutations in enzymes responsible for
oxysterol formation can lead to disease in humans. One example is
cytochrome P450 (CYP) 27A1, a sterol (25R) 26-hydroxylase, whose
deﬁciency is the cause of cerebrotendinous xanthomatosis (CTX), a
rare disease which can present in early infancy with cholestatic
liver disease [10], in early childhood with chronic diarrhoea and
cataracts, in later childhood with tendon xanthomata, learning
difﬁculties or psychiatric illness, and in adult life with spastic
paraparesis, a fall in IQ or frank dementia, ataxia and/or dysarthria
[11]. CTX is usually diagnosed only in the adolescent and adult.
Deﬁciency in another enzyme, CYP7B1, an oxysterol 7a-hydroxy-
lase, can lead to liver disease in infants and spastic paraplegia in
adults (hereditary spastic paraplegia type 5, SPG5) [12]. Deﬁciency
in CYP7A1, cholesterol 7a-hydroxylase, can lead to hyperlipidemia
and gallstones [13].
The brain contains a high proportion of the body’s cholesterol
[1], the majority of which is present in myelin sheaths of
oligodendrocytes but much of cholesterol metabolism is in
neurons where CYP46A1 oxidises it to 24S-hydroxycholesterol
(24S-HC) [14]. Unlike cholesterol, 24S-HC can pass the blood brain
barrier (BBB) and be exported from brain [15]. This makes 24S-HC a
target for analysis in plasma in the hope of early diagnosis of
neurodegenerative disease e.g. Alzheimer’s disease (AD), Parkin-
son’s disease (PD) [16,17].
Oxysterol synthesis is an important part of the immune
response to pathogens. Macrophages, a type of white blood cell
which play a critical role in immunity can make high levels of 25-
hydroxycholesterol (25-HC), through up-regulation of cholesterol
25-hydroxylase (CH25H), when stimulated by bacteria [18,19] or
viruses [20], and its metabolite 7a,25-dihydroxycholesterol
(7a,25-diHC) can activate a G protein-coupled receptor (GPCR)
called Epstein–Barr virus-induced gene 2 (EBI2, GPR183) and
oxysterol gradients guide migration of EBI2 expressing immune
cells [21,22] many of which have been implicated in shaping the
adaptive and innate immune response. The exact role of 25-HC
itself in immunity is yet to be uncovered, although Reboldi et al.showed that 25-HC is a mediator of negative feedback towards
interleukin 1 (IL-1) family cytokine production and inﬂammasome
activity, through binding to INSIG (insulin induced gene) and
antagonising the sterol response element-binding protein-2
(SREBP-2) driven mevalonate pathway, thereby, reducing Il1b
transcription and repressing IL-1-activating inﬂammasomes [23].
Most recently, oxysterols have been implicated in neurogenesis
[24] and their relatives, cholestenoic acids, in the regulation of
survival of motor neurons [25]. Their involvement in these
processes is through interaction with the liver X receptors (LXRs),
known receptors of oxysterols [26,27].
2. Metabolism of cholesterol and its precursors to oxysterols
2.1. Enzymatic metabolism of cholesterol
The ﬁrst step in steroid hormone biosynthesis is oxidation of
cholesterol to 22R-hydroxycholesterol (22R-HC) and on to
20R,22R-dihydroxycholesterol (20R,22R-diHC) and ultimately to
pregnenolone by the enzyme CYP11A1 [28]. Interestingly, 22R-HC
and 20R,22R-diHC have been reported to be present in newborn
and adult mouse brain supporting the concept to steroidogenesis
in brain [29,30] (Fig. 1A, Supplementary Table S1). Both these
oxysterols activate LXRs [28]. The ﬁrst step of the neutral pathway
of bile acid biosynthesis is oxidation of cholesterol to 7a-
hydroxycholesterol (7a-HC) by hepatic CYP7A1, 7a-HC is then
oxidised to 7a-hydroxycholest-4-en-3-one (7a-HCO) by hydrox-
ysteroid dehydrogenase (HSD) 3B7 or alternatively 7a-HC is
further hydroxylated to 7a,(25R)26-dihydroxycholesterol (7a,
(25R)26-diHC) by CYP27A1 (Fig. 1B). Note, introduction of a
hydroxy group at the terminal carbons, C-26 or C-27, of the
cholesterol side-chain introduces R or S stereochemistry at C-25.
To avoid confusion we deﬁne the stereochemistry when known,
and use the systematic numbering of carbon atoms according to
IUPAC rules [31]. 7a-HCO can be similarly hydroxylated by
CYP27A1 and 7a,(25R)26-diHC can be oxidised by HSD3B7, both
to give 7a,(25R)26-dihydroxycholest-4-en-3-one (7a,(25R)26-
diHCO). Alternatively, hydroxylation can be at C-12a through
CYP8B1 to generate 7a,12a-dihydroxycholest-4-en-3-one
(7a,12a-diHCO) on the pathway to cholic acid, and oxidation of
both 7a,12a-diHCO and 7a,(25R)26-diHCO by CYP27A1 can occur
to generate the (25R)26 acids, 7a,12a-dihydroxy-3-oxocholest-4-
en-(25R)26-oic (7a,12a-diH,3O-CA) and 7a-hydroxy-3-oxochol-
est-4-en-(25R)26-oic (7aH,3O-CA) acids, respectively. Each of
these metabolites can be observed in human and in mouse plasma
(Table 1, Table S1) [32–36]. Prior to formation of (25R)26 acids the
3-oxo-4-ene group can be reduced by two successive aldoketo
reductase (AKR) enzymes, 1D1 and 1C4, to a 3a-hydroxy-5b-
hydrogen conﬁguration, but metabolites with these structures are
not routinely observed in plasma. Of the enzymatically formed
oxysterols, 7a-HC can also be formed by autoxidation of
cholesterol ex vivo, so there is always a concern over concentration
reported in the literature for this oxysterol [2]. The ﬁrst step of the
acidic pathway of bile acid biosynthesis is the conversion of
cholesterol to (25R)26-hydroxycholesterol ((25R)26-HC) by
CYP27A1 (Fig. 1B). (25R)26-HC can be oxidised further to the
(25R)26 acid, 3b-hydroxycholest-5-en-(25R)26-oic acid (3b-HCA),
by CYP27A1 or to 7a,(25R)26-diHC by CYP7B1. Both of these
(A)
(B)
Fig. 1. (A) Early steps of steroid hormone biosynthesis. (B) Conversion of cholesterol to bile acids.
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(25R)26-oic acid (3b,7a-diHCA) or alternatively 7a,(25R)26-diHC
can be oxidised to 7a,(25R)26-diHCO by HSD3B7. 7a,(25R)26-
diHCO is then further oxidised to 7aH,3O-CA by CYP27A1 while is
3b,7a-diHCA is oxidised by HSD3B7 also to 7aH,3O-CA. While theneutral pathway of bile acid biosynthesis is hepatic, the acidic
pathway can proceed extrahepatically [37]. (25R)26-HC is largely
biosynthesised in lung [38]. Both 7a,(25R)26-diHCO and 7aH,3O-
CA are exported from brain while (25R)26-HC is imported to brain
from the circulation indicating that the bile acid biosynthesis
Table 1
Sterols including oxysterols, cholenoic and cholestenoic acids in human plasma/serum and CSF. All concentrations in ng/mL.
Plasma or serum CSF
Sterol systematic name
(common name)
Free sterols
LC–MS with
EADSAa,b,c,d
NIST SRM 1950
Free sterols
LC–MS with
EADSAh
NIST SRM 1950
Free or Total
sterols
LC–MSi,j
Cooper Instk, Dallas
Heartl,
Total sterols
LC–MS
Free or Total
sterols
LC–
MSm,n,o,p,q,r,s,t,u,v
Free or Total
sterols
GC–MSc,w,x,y,z,A,B
Free sterols
LC–MS withC,D,E
or withoutF
EADSA
Total sterols
GC–MSG,H
3b-Hydroxycholest-5-en-24-one
(24-Oxocholesterol)
0.59 0.85a,e 0.14 0.03h,e 3.7i 6.02.2k – – – –
0.240.06d,e 5(0.4–116)l
3b-Hydroxycholest-5-en-24S,25-epoxide
(24S,25-Epoxycholesterol)
0.59 0.85a,f
0.240.06d,f
0.140.03h,f 1.8i 1.84.4k
1(0.1–56)l
2 2m – – –
7a-Hydroxy-26-nor-cholest-4-ene-3,24-dione <0.2a,g 0.040.02g,h – – – – 0.200.08C,g –
0.370.05b,g 0.710.09D,g
0.2 0.2d,g
Cholest-5-ene-3b,4b-diol
(4b-Hydroxycholesterol)
– – 5.46 0.19j 53.12.4k 7740m 2910w – –
22.10.8j 36(9–500)l 22.59.5n 12.377.32c
31.4i 48.52.0o 14.150.96B
51.92.4s
Cholest-5-ene-3b,24S-diol
(24S-Hydroxycholesterol)
6.86 0.31a 5.460.05h 2.55 0.12j 56.12.1k 12.3 4.79r 362.82x 0.020.01C 1.5(1.2–2.3)G
12.880.45b 19.70.8j 57(10–314)l 8.64t 6424x 0.080.00D
7.00 3.15c 44.6i 5112m 33.1813.81c 0.24F
7.110.40d 6414p 55.462.07B
60.41.6o
64.41.8s
Cholest-5-ene-3b,25-diol
(25-Hydroxycholesterol)
4.06 0.22a 0.700.02h 0.36 0.02j 11.82.4k 3111m 0.82 0.32x 0.030.01C –
1.180.07b 8.11.2j 8(1–56)l 14.01.1o 23x 0.030.00E
1.25 0.82c 5.7i 14.91.1s 5.832.32c 0.030.01F
3.96 0.27d 6.960.64B
Cholest-5-ene-3b,(25R)26-diol
((25R)26Hydroxycholesterol)
19.12 0.70a 10.33 0.60h 5.14 0.29j 151.42.0k 17.7 8.5r 31 (13–41)y 0.030.01C 0.8(0.7–1.0)G
23.950.60b 21616j 150(25–990)l 11735m 13.861.54x 0.15 0.00D
11.63 7.37c 131.0i 12030p 15443x 0.10 0.01E
18.99 0.85d 129.94.1o 43.6730.61c
139.04.7s 203.5815.90B
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Table 1 (Continued)
Plasma or serum CSF
Sterol systematic name
(common name)
Free sterols
LC–MS with
EADSAa,b,c,d
NIST SRM 1950
Free sterols
LC–MS with
EADSAh
NIST SRM 1950
Free or Total
sterols
LC–MSi,j
Cooper Instk, Dallas
Heartl,
Total sterols
LC–MS
Free or Total
sterols
LC–
MSm,n,o,p,q,r,s,t,u,v
Free or Total
sterols
GC–MSc,w,x,y,z,A,B
Free sterols
LC–MS withC,D,E
or withoutF
EADSA
Total sterols
GC–MSG,H
Cholest-5-ene-3b,7b-diol
(7b-Hydroxycholesterol)
0.00 0.32a 0.480.28h – – – 0.45 0.39x 0.01  0.01C 1.1(0.8–1.2)G
1.09 0.13b 3  5x 0.03  0.03E
0.33 0.61c 13.0511.26c
1.02 0.58d 34.689.96B
3b-Hydroxycholest-5-en-7-one
(7-Oxocholesterol)
3.77 1.29a 0.590.33h 5.513.16j 844.5k 29(11.4–44.4)q 13.643.96x 0.030.02C 0.9(0.7–2.3)G
3.14 0.14b 49.133.4j 39(8–375)l 2214x
3.58 4.00c 24.0i 10.746.12c
4.98 2.25d 69.5426.06B
7a-Hydroxycholest-4-en-3-one 2.29 0.25a 10.01 1.65h – – 26.12.9o 24.45.4z – –
8.61 0.47b 6.4 5.3u 10 (3–14)y
0.88 2.09c 38 18v
2.43 0.37d 27.53.0s
Cholest-5-ene-3b,7a-diol
(7a-Hydroxycholesterol)
0.82 0.39a 9.522.64h 4.68 0.63j 158.73.2k 14582n 14 (7–15)y 0.020.02C 1.5(1.1–2.3)G
3.64 0.29b 13527j 90(12–2762)l 136.512.0s 7.31 2.15x 0.030.02D
0.33 0.41c 91.8i 4348x
1.30 0.39d 8.999.34c
65.848.10B
Cholest-4-ene-3b,6-diol or Cholest-5-ene-3b,6-diol
(6-Hydroxycholesterol)
1.68 1.07a – – – – – 0.030.02C –
0.28 0.48c 0.15 0.04D
1.96 0.50d
7a,25-Dihydroxycholest-4-en-3-one 1.24 0.20a 1.100.04h – – – – 0.040.00D –
0.96 0.05b
1.46 1.29c
1.10 0.32d
Cholest-5-ene-3b,7a,25-triol
(7a,25-Dihydroxycholesterol)
<0.20a 0.120.04h – – – – 0.030.00D –
0.23 0.01b
0.35 0.13c
7a,(25R)26-Dihydroxycholest-4-en-3-one 5.55 0.41a 3.63 0.16h – – – 3 (2–10)y 0.050.00D –
2.69 0.11b
2.22 1.04c
5.100.56d
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Cholest-5-ene-3b,7a,(25R)26-triol
(7a,(25R)26-Dihydroxycholesterol)
1.65 0.39a 0.260.09h 9.6i 102.4k – <1y 0.030.00D –
0.46 0.02b 10(2–90)l
0.60 0.34c
0.92 0.49d
7a,12a-Dihydroxycholest-4-en-3-one – – – – 0.4 0.27u – –
Cholest-5-ene-3b,7a,12a-triol (7a,12a-
Dihydroxycholesterol)
– – – – – – –
3b-Hydroxychol-5-en-24-oic acid 1.78 0.25a 2.480.32h – – – – – –
2.46 0.09b
1.03 0.99c
0.83 0.14d
7a-Hydroxy-3-oxochol-4-en-24-oic acid 1.910.26a 2.030.27h – – – – 0.170.09C –
2.43 0.13b 0.51 0.09D
1.77 1.24c
1.17 0.23d
3b,7a-Dihydroxychol-5-en-24-oic acid 4.13 0.77a 1.04 0.10h – – – – – –
1.83 0.10b
1.002.11c
1.52 0.34d
3b-Hydroxycholest-5-en-(25R)26-oic acid 82.603.50a 62.48 2.39h – – – 67.2 27.9A 0.420.19C –
83.832.98b 75.5 5.9z 1.46 0.10D
50.2625.17c 57(39–64)y 0.96  0.10E
81.12 4.31d
3b,7b-Dihydroxycholest-5-en-26-oic acid 5.36 0.81a 2.740.18h – – – – 0.170.16C
2.79 0.09b 0.560.03D
2.72 1.27c 0.400.04E
1.67 0.32d
3b,22,25-Trihydroxycholest-5-en-24-one 9.63 1.46a,g 8.020.72h,g – – – – 0.27 0.03D –
4.070.22b,g
5.370.64d
7a-Hydroxy-3-oxocholest-4-en-(25R)26-oic acid 63.895.44a 58.275.48h – – – 81.7 27.9A 7.172.83C 15 3H
50.732.07b 27.43.5z 19.48 2.49D
50.6819.90c 85(67–93)y 17.401.09E
65.27 6.22d
3b,7a-Dihydroxycholest-5-en-(25R)26-oic acid 47.42 6.61a 19.22 1.92h 38.9 25.6A 5.880.46D –
19.30 0.73b 29.5 4.9z 2.120.39E
18.5710.29c 30(25–38)y
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Table 1 (Continued)
Plasma or serum CSF
Sterol systematic name
(common name)
Free sterols
LC–MS with
EADSAa,b,c,d
NIST SRM 1950
Free sterols
LC–MS with
EADSAh
NIST SRM 1950
Free or Total
sterols
LC–MSi,j
Cooper Instk, Dallas
Heartl,
Total sterols
LC–MS
Free or Total
sterols
LC–
MSm,n,o,p,q,r,s,t,u,v
Free or Total
sterols
GC–MSc,w,x,y,z,A,B
Free sterols
LC–MS withC,D,E
or withoutF
EADSA
Total sterols
GC–MSG,H
39.403.95d – – –
Values for free sterols are given in italics, total sterols (free + esteriﬁed with fatty acids) in bold. – Signiﬁes not measured. SE = standard error, SD= standard deviation.
a From Grifﬁths et al. [93],n =84, mean SE.
b From Crick et al. [32], pool of 8 adults, mean SE, n =5 measurements.
c From Iuliano et al. [34], n =18, coronary heart disease patients, mean SD.
d From Theoﬁlopoulos et al. [25], n =50, mean SE.
e In EADSA analysis 24S,25-epoxycholesterol isomerises to 24-oxocholesterol.
f Total 24S,25-epoxide given including products of EADSA side-reactions.
g Authentic standard not available. Presumptive identiﬁcation based on retention time, exact mass and MSn spectra.
h From Grifﬁths et al. [60], n =3 independent sample preparations, mean SD.
i From McDonald et al. [35].
j From Quehenberger et al. [69], n =3, mean SE.
k From McDonald et al. [35], n =200, meanRSE.
l From Stiles et al. [36], n =3230, median (range).
m From Honda et al. [73], n =19, mean SD.
n From van de Merbel [108], n =129, mean SD.
o From Ikegami et al. [109], n =36, mean SE.
p From Burkard et al. [71], n =22, mean SD.
q From Jiang et al. [77], n =89, mean(range).
r From Bandaru et al. [70], n =12, mean SD.
s From Ikegami et al. [74], n =113, mean SE.
t From Sidhu et al. [75], pooled plasma sample.
u From DeBarber et al. [79], n =20, mean SD.
v From DeBarber et al. [80], n =9, mean SD.
w From Bodin et al. [110], n =125, mean SD.
x From Dzeletovic et al. [40], n =31, mean SD, free oxysterol levels re-calculated from% of unesteriﬁed oxysterols (n =6).
y From Axelson and Sjövall [111], n =20, median (upper quartile–lower quartile) for acids, n =6 for hydroxysterols average (range).
z FromMeaney et al. [39], n =9, mean SE, blood taken from brachial artery, values not signiﬁcantly different from the jugular vein except of 7a-hydroxy-3-oxocholest-4-enoic acid which is elevated by 2.81.3 ng/mL in venous
blood. 7a-Hydroxycholest-4-en-3-one measured by LC–UV.
A From Axelson et al. [37], n =11, mean SD.
B From Schött et al. [65], representative plasma sample, mean SD, n =6 measurements.
C From Ogundare et al. [95], n =9, mean SD.
D From Theoﬁlopoulos et al. [25], pool of 15CSF samples, mean SE, n =3 measurements.
E From Theoﬁlopoulos et al. [25], n =18, mean SE.
F From Sidhu et al. [75], pooled CSF sample.
G From Leoni et al. [63], n =24, median (25–75% conﬁdence interval).
H From Saeed et al. [68], n =8, mean SD.
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Fig. 2. Biosynthesis and metabolism of (A) 24S-HC, (B) 25-HC and (C) 7-OC and 7,8-EC.
W.J. Grifﬁths et al. / Journal of Steroid Biochemistry & Molecular Biology 162 (2016) 4–26 11pathway is active in brain [34,39]. All of the above metabolites of
the acidic pathway of bile acid biosynthesis are observed in human
plasma [32,34,36]. In plasma oxysterols are found predominately
esteriﬁed to fatty acids, the ratio of esteriﬁed to free oxysterols is of
the order of about 10:1 [40].
The major oxysterol exported from brain is 24S-HC, this is
metabolised in liver to 7a,24S-dihydroxycholesterol (7a,24S-diHC)
by CYP39A1 and further to 7a,24S-dihydroxycholest-4-en-3-one
(7a,24S-diHCO) (Fig. 2A) [9]. Low levels of 7a,24S-diHC or 7a,24S-
diHCO have been observed in mouse cerebrospinal ﬂuid (CSF)
(Table S1) [33], and we have recently identiﬁed 7a,24S-diHCO in
mouse and porcine brain [Grifﬁths, unpublished data]. Cyp39a1 is
reported to be expressed in the somatosensory cortex of adult
mouse brain [41]. The Allen Brain Atlas [41], http://www.brain-
map.org/, is an excellent resource for gene expression data in brain.
An alternative route of metabolism of 24S-HC is through
conjugation with sulphuric and/or glucuronic acids and excretion
in urine [42,43]. 25-HC is usually present at low levels in biological
samples (Table 1, Table S1). As is the case with 7a-HC, it can be
formed enzymatically and by autoxidation, and again there is
always doubt whether the 25-HC observed is formed in vivo or ex
vivo during sample handling or storage [2]. High levels of 25-HC areformed by macrophages following bacterial or viral challenge, in
which case plasma levels are elevated [18–20]. 25-HC is
metabolised by CYP7B1 to 7a,25-diHC and on to 7a,25-dihydrox-
ycholest-4-en-3-one (7a,25-diHCO) by HSD3B7 (Fig. 2B).
Recently it was reported by Nelson et al. [44] and by Wu et al.
[45] that (25R)26-HC (commonly referred to by the non-
systematic name 27-hydroxycholesterol) is associated with ER-
positive breast cancer. Earlier studies had established (25R)26-HC
as a selective estrogen receptor modulator [46] and Nelson et al.
showed that (25R)26-HC increased ER-dependent growth and
LXR-dependent metastasis in a mouse model of breast cancer [44].
High grade tumours, tumour cells and tumour associated macro-
phages were found to express high levels of CYP27A1 [44]. Wu
et al. [45] found that the (25R)26-HC content of normal breast
tissue was increased in ER+ breast cancer patients compared to
cancer-free controls, and in tumours (25R)26-HC was further
elevated. Both Nelson et al. and Wu et al. found that increased (25R
)26-HC concentrations correlated with reduced expression of
CYP7B1, the enzyme responsible for metabolism of (25R)26-HC to
7a,(25R)26-diHC [44,45]. It is now timely for detailed studies of
the oxysterolome in relation to cancer in general and breast cancer
in particular.
Fig. 3. Simpliﬁed version of the cholesterol biosynthesis pathway.
12 W.J. Grifﬁths et al. / Journal of Steroid Biochemistry & Molecular Biology 162 (2016) 4–262.2. Enzymatic metabolism of cholesterol precursors
7-OC is a notorious autoxidation product [2], however, it has
recently been shown that it can be formed from the cholesterol
precursor 7-dehydrocholesterol (7-DHC) by the enzyme CYP7A1
[8]. 7-OC can be metabolised by HSD11B1 to 7b-hydroxycholes-
terol (7b-HC) [47]. 7b-HC can also be formed by autoxidation and
is another oxysterol that can be formed endogenously and ex vivo
(Fig. 2C).24S,25-Epoxycholesterol (24S,25-EC) is an unusual oxysterol in
that it is formed via a shunt of the cholesterol biosynthesis
pathway, also known as the mevalonate pathway (Fig. 3) [48]. In
the cholesterol synthesis pathway, prior to cyclisation to lano-
sterol, squalene is oxidised to 2,3S-oxidosqualene (squalene-2,3S-
epoxide) by squalene epoxidase (SQLE). SQLE can introduce a
second oxygen atom with the formation of 2,3S;22S,23-dioxidos-
qualene. 2,3S;22S,23-Dioxidosqualene is then cyclised by lano-
sterol synthase (LSS) to give 24S,25-epoxylanosterol. Lanosterol
(A)
Fig. 4. Oxysterols formed by reactive oxygen species or autoxidation ex vivo .
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while 24S,25-epoxylanosterol follows a parallel pathway, but with
the exclusion of the enzyme 24-dehydrocholesterol reductase
(DHCR24), to give 24S,25-EC as the ultimate product [49]. Recently,
it has been reported that 24S,25-EC can also be formed from
desmosterol by CYP46A1 [50]. 24S,25-EC is a ligand to the LXRa
and LXRb nuclear receptors [24,26,27]. It is a prominent oxysterol
in developing and newborn brain, where levels of 24S-HC are low,
(Table S1) [24,51,52] and has been ascribed neurogenerative
properties in the ventral midbrain [24]. Evidence from the Cyp7b1
knockout mouse where 24S,25-EC levels are elevated in brain
indicates that 24S,25-EC is metabolised through 7a-hydroxylation
by CYP7B1 [52]. Interestingly, levels of 24S,25-EC are reduced in
the Cyp46a1 knockout mouse both in brain and plasma [30],
[Grifﬁths unpublished data], while elevated in the CYP46A1 over
expressing mouse [Grifﬁths unpublished data]. These observations
may be explained by 24S,25-EC being formed from desmosterol by
CYP46A1 or alternatively through differential regulation of the
mevalonate pathway by negative-feedback by cholesterol whose
synthesis along with that of desmosterol is reduced in brain of the
Cyp46a1 knockout mouse in response to its reduced metabolism
[30,53]. 24S,25-EC is technically difﬁcult to analyse as it is
susceptible to acid catalysed hydration and methanolysis.
Besides being a substrate for CYP46A1, desmosterol is also a
substrate for CYP7A1 and CYP27A1 with the formation of 7a-
hydroxydesmosterol (7a-HD) and 26-hydroxydesmosterol (26-
HD), respectively (Table S1) [29,54].
2.3. Metabolism via reactive oxygen species
7-OC, 7a-HC, 7b-HC, 5a,6a-epoxycholesterol (5a,6a-EC) and
5b,6b-EC have been proposed to be formed via ROS in vivo while
cholestane-3b,5a,6b-triol (3b,5a,6b-triol) is formed from 5,6-EC
by the enzyme cholesterol epoxide hydrolase (ChEH). As the in vivo
ROS-formed sterols can also be formed from cholesterol ex vivo
analysis is challenging [55]. Both 7-OC and 3b,5a,6b-triol have
been linked to the lipid storage disease Niemann-Pick disease type
C1 (NPC1) (Fig. 4). An alternative mechanism for metabolism of
5a,6a-EC is aminolysis with histamine to give dendrogenin A
(DDA, Fig. 4). Low levels of endogenous DDA are found in brain and
also in other tissues and plasma [56]. DDA is not detected in cancer
cell lines and is present at lower concentrations in breast tumours
than normal tissue suggesting that DDA may be deregulated during
carcinogenesis [56,57].3. Classical analytical methods
3.1. Avoiding ex vivo autoxidation
Whether the ultimate analytical method is gas
chromatography–mass spectrometry (GC–MS) or liquid chroma-
tography (LC)–MS precautions need to be taken to minimise ex vivo
autoxidation. For example, for plasma or serum analysis collection
of blood into EDTA containing vacutainers is preferred, EDTA
chelates Fe2+ and thereby prevents Fenton chemistry and the
generation of free radicals. Following centrifugation to prepare e.g.
plasma/serum the antioxidant butylated hydroxytoluene (BHT) is
often added. An alternative is to add the peroxide reducing agent
triphenylphosphine (TPP) in addition to BHT [58]. To minimise
oxidation from atmospheric oxygen sample preparation steps can
be performed under Ar. The precautions taken in the authors
laboratory to minimise ex vivo autoxidation are to separate sterols
from oxysterols in a ﬁrst step of sample preparation, thereby
minimising cholesterol and 7-DHC ex vivo autoxidation artefacts at
source, and to perform all drying steps under vacuum. It may also
be beneﬁcial to evaluate sample preparation protocols by adding
exogenous [2H7]cholesterol and [2H7]7-DHC to the sample matrix
and following the formation of heavy-isotope labelled oxysterols
during sample preparation [58,59].
3.2. Gas chromatography–mass spectrometry (GC–MS)
The classical method for oxysterol analysis is by GC–MS. The
limitation of this method is that it is not applicable to oxysterol
conjugates, requiring hydrolysis of fatty acid esters, solvolysis of
sulphates, and hydrolysis of glucuronic acid acetals. Never-the-
less, GC–MS provides the “gold standard” method for oxysterol
analysis [60]. The “gold standard” method originates from studies
in the laboratory of Björkhem and Diczfalusy and is described in
the classic publication by Dzeletovic et al. [40]. This methodology
has been adopted by many groups worldwide [61–65]. In brief, the
method for plasma analysis is as follows. Blood is collected in EDTA
containing vacutainers, and following centrifugation to prepare
plasma, antioxidant BHT is added as are deuterated internal
standards. Alkaline hydrolysis is performed under argon using
0.35 M ethanolic KOH for 2 h at room temperature. The solution is
neutralised with phosphoric acid and sterols extracted into
chloroform. Solvent is evaporated and the residue dissolved in
toluene. Oxysterols are then separated from cholesterol on a silica
14 W.J. Grifﬁths et al. / Journal of Steroid Biochemistry & Molecular Biology 162 (2016) 4–26cartridge, eluted and dried down and derivatised to trimethylsilyl
(TMS) ethers with pyridine/hexamethyldisilazane/trimethylchlor-
osilane (3:2:1, v/v/v) at 60 C for 30 min (Fig. 5A). The product is
dried down and re-dissolved in hexane for injection onto GC–MS.
Analysis is usually by selected ion monitoring (SIM) on a single
quadrupole MS. This method with minor modiﬁcations is also
applicable to analysis of CSF [63], brain tissue [66] and cells [67].
Sensitivity is of the order of 1 ng/mL from 0.5 mL of CSF [63] and
<0.5 ng/mL from 0.5 mL of serum [65].
Björkhem and colleagues have modiﬁed their GC–MS method
so that it is also applicable to cholestenoic acids, speciﬁcally
7aH,3O-CA in CSF [68]. Cholestenoic acids are extracted from CSF
into ether following acidiﬁcation with 0.1 M HCl. After washing of
the ether phase with water until neutral the ether is evaporated
and the cholestenoic acids methylated with TMS-diazomethane in
hexane in a solution of methanol and toluene (Fig. 5B). After 5 min
the solvent and excess reagent is removed by evaporation. The
methylated acids are converted to TMS ethers as above and
analysed by GC–MS. The method is sufﬁciently sensitive to detect
ng/mL concentrations of 7aH,3O-CA from 1 mL of CSF [68]. An
important consideration for sterols with a 3-oxo-4-en-7-ol group
is the lability of the hydroxy group both in acid and base solution.
This precludes the use of an alkaline hydrolysis step and requires
careful use of any acids. To correct for any loses by dehydration
Saeed et al. [68] included an isotope labelled version of 7aH,3O-CA
during sample preparation.
4. Newer analytical methods
4.1. Liquid chromatography–mass spectrometry (LC–MS) without
derivatisation
McDonald, Russell and co-workers have developed a high
throughput LC–MS method for oxysterol analysis [35,69] and most
impressively implemented the method in the analysis of 3230 se-
rum samples from a clinically well-deﬁned cohort, the Dallas Heart
Study (Table 1) [36]. Their method is as follows. In brief, sterols and
oxysterols are extracted into dichloromethane/methanol (1/1, v/v)
containing BHT and deuterated internal standards. Following
centrifugation the supernatant is hydrolysed with KOH in
dichloromethane/methanol (1/1, v/v) for 1.5 h at 35 C. PBS is
added to give a two phase system and the organic phase retained.
Solvent is evaporated and the residue re-dissolved in hexane and
sterols and oxysterols separated from other lipids on an amino-
propyl cartridge. The sterol and oxysterol fraction is reconstituted
in 90% methanol for injection on a reversed phase LC column.
McDonald and Russell use a Poroshell 120 SB-C18 HPLC column
(150  2.1 mm, 2.7 mM particle size) and an acetonitrile/propan-2-
ol/5% ammonium acetate gradient. Detection is by electrospray
ionisation (ESI) tandem mass spectrometry (MS/MS) exploiting
multiple reaction monitoring (MRM) [35]. The MRM transitions
utilised are [M + NH4]+! [MH  nH2O]+ or [M + H]+! [MH-nH2O]+.
The sensitivity of the method allows the detection of 1 ng/mL
oxysterol from 200 mL of plasma. McDonald and Russell using this
method analysed a pooled plasma sample from NIST representa-
tive of the population of the USA (NIST Standard Reference
Material (SRM) 1950) [35,69] and reported the concentrations of 10
oxysterols (Table 1). Using this method they went on to analyse
3230 samples from the Dallas Heart Study. The method is
applicable to >60 sterols and vitamins D metabolites, and they
routinely quantiﬁed 29 sterols including 15 oxysterols in serum
[36]. There are numerous other LC–MS protocols for oxysterol
analysis [70–72], but none are as extensive as that developed by
McDonald and Russell or have been exploited on such a high
numbers of samples [36].4.2. 2 LC–MS with derivatisation
Although the LC–MS method described above can be used on a
high throughput format, 50 samples could be extracted in a single
day [35], it relies on chromatographic separation of isomeric
oxysterols and the availability of authentic standards. This is a
consequence of [M + NH4]+ or [M + H]+ ions of isomeric oxysterols
giving a similar MS/MS spectrum. This is evident in the excellent
library of MS/MS spectra found on the Lipid Maps website http://
www.lipidmaps.org/data/standards/. In addition, oxysterols are
neither basic or acidic, hence do not readily form [M + H]+,
[M + NH4]+ or [M  H] ions and do not give strong signals in ESI,
atmospheric pressure chemical ionisation (APCI) or other desorp-
tion ionisation methods. In an effort to improve signal, derivatisa-
tion methods have been designed which in some cases also provide
added structural information.
4.2.1. Derivatisation to picolinyl esters
Honda et al. [73] have developed a sensitive LC–MS/MS method
exploiting derivatisation of oxysterols to picolinyl esters which is
applicable to 5 mL of serum (Fig. 5C). Alkaline hydrolysis (1 N KOH
at 37 C, 1 h) is carried out after the addition of BHT and isotope
labelled standards, then oxysterols are extracted into n-hexane. To
the dried extract, freshly prepared derivatisation mixture of 2-
methyl-6-nitrobenzoic anhydride (1 mg), 4-dimethylaminopyri-
dine (3 mg), picolinic acid (8 mg), pyridine (150 mL) and triethyl-
amine (20 mL) is added. After heating for 60 min at 80 C, the
derivatised oxysterols are extracted into n-hexane and separated
from insoluble material by centrifugation. The supernatant is dried
down and reconstituted into acetonitrile for LC-ESI–MS/MS
analysis using a Hypersil Gold (150  2.1 mm, 3 mm particle size)
reversed phase column and an acetonitrile/methanol/0.1% acetic
acid gradient. Hydroxycholesterols tend to give dipicolinates and
[M + Na]+ ions in ESI. When MS/MS is performed the dominant
fragment ions are [M + Na-123]+ and m/z 146 which correspond to
the loss of picolinic acid from the [M + Na]+ ion, and to sodiated
picolinic acid, respectively. These fragmentations can be exploited
for MRM analysis. Honda et al. [73] were able to detect oxysterols
at a level of 2 ng/mL from only 5 mL of serum. Using this protocol
Honda et al. measured the concentration of seven oxysterols in
human serum. Ikegami et al. [74] have subsequently exploited
their method in the investigation of a large cohort of patients with
hepatitis C virus infection (n = 55) and healthy controls (n = 113).
They determined the serum concentration of 6 oxysterols and
found that the levels of 7a-HC, 4b-hydroxycholesterol (4b-HC)
and 25-HC were elevated in patient samples. The concentrations of
these oxysterols fell after treatment with anti-viral therapy. In
contrast the concentrations of 24S-HC, 26-HC and 7a-HCO did not
vary between patient and control samples.
4.2.2. Derivatisation to nicotinyl esters
Nicotinic acid (pyridine-3-carboxylic acid) has a very similar
structure to picolinic acid (pyridine-2-carboxylic acid) and has
been used as a derivatisation reagent by Sidhu et al. to measure free
24S-HC in plasma and CSF (Fig. 5D) [75]. They found that
hydroxycholesterols give double derivatives which ionise as
[M + H]+ and [M + 2H]2+ ions in ESI. They exploited the 307.22
+! 124.0+ MRM transition corresponding to [M + 2H]2+ fragment-
ing to protonated nicotinic acid. Sidhu et al. suggest that free 24S-
HC in CSF is adsorbed by polypropylene surfaces based on an
experiment in which they transferred a CSF sample to ﬁve
consecutive polypropylene tubes and achieved a recovery of only
45%. To avoid this they suggest collecting CSF in tubes preloaded
with 2-hydroxypropyl-b-cyclodextrin (HP-b-CD). Their method
for sample preparation is as follows. Plasma (50 mL) with added
internal standards is diluted with 50 mM ammonium acetate, 1%
(A)
(B)
(C)
(D)
Fig. 5. Derivatisation of oxysterols or cholestenoic acids to (A) TMS ethers [40], (B) TMS ether methyl esters [68], (C) bis picolinyl esters [73], (D) bis nicotinyl esters [75], (E) N,
N-dimethylglycyl esters [76], (F) O- (3-trimethylammonium-propyl) oximes [79], (G) Girard hydrazones. Fragment ions formed by MS/MS are indicated. See Fig. S1 for
fragmentation mechanisms suggested by Murphy [107] for GP-derivatives.
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(A)
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Fig. 6. (A) Synthesis of the GP reagent and different isotope labelled versions of the GP reagent (* = 15N or 13C) [32]. Schematic illustrating application of (B) differential mass
tags and (C) isobaric mass tags. Modiﬁed from Crick et al. [32].
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butylether (MTBE). Likewise for CSF, internal standards are added
to CSF (200 mL) and oxysterols extracted into MTBE. The MTBE is
evaporated and a derivatisation mixture consisting of 63 mg N,N
-diisopropylcarbodiimide, 62 mg nicotinic acid, and 61 mg of 4-
(dimethylamino) pyridine in chloroform added. After heating at
50 C for 1 h, chloroform is evaporated and the residue re-dissolved
in methanol for LC-ESI–MS/MS analysis. Sidhu et al. used a trap
column (Phenomenex C18, 4  3 mm) prior to an analytical column
(Eclipse XDB-C18, 3  100 mm, 3.5 mm particle size), both reversed
phase, and a water/acetonitrile/methanol/0.1% formic acid gradi-
ent [75]. From 50 mL of plasma and 200 mL of CSF they were able to
detect and quantify 24S-HC at 1 ng/mL and 0.025 ng/mL concen-
trations, respectively. They indicate that they have analysed over
1700 samples using this method, but in their 2015 publication just
gave data for three patient samples, one pooled plasma sample and
one pooled CSF sample [75]. The pooled plasma sample had a 24S-
HC concentration of 8.64 ng/mL while the pooled CSF concentra-
tion was 0.244 ng/mL. These values are in moderate agreement
with earlier data for free 24S-HC determined by others, see Table 1.
Very interestingly, when CSF was analysed from patients suffering
from NPC1 disease, a lysosomal storage disorder, who were
administered HP-b-CD intracerebroventricularly as part of a
clinical trial in NPC1 patients the CSF level of 24S-HC increased
20–50 fold [75].Fig. 7. LC–MS(MS3) analysis of typical human plasma sample using EADSA technology 
without cholesterol oxidase. MS3 fragmentation, [M]+! [M-Py]+!, of peaks eluting at (B)
Data generated on an Orbitrap Elite. Py corresponds to pyridine. Fragmentation mecha4.2.3. Derivatisation to N,N-dimethylglycine esters
Jiang and Han have also utilised derivatisation to improve the
LC–MS/MS analysis of oxysterols (Fig. 5E) [76,77]. They exploited
derivatisation to N,N-dimethylglycine esters and APCI. In brief,
oxysterols are extracted from plasma (50 mL) into methanol
containing internal standards and after centrifugation to remove
proteins the extract is dried down. The derivatisation mixture
(20 mL) of 0.5 M dimethylglycine, 2 M 4-dimethylaminopyridine in
chloroform and 1 M 1-ethyl-3-(3-dimethylaminopropyl) carbodii-
mide in chloroform is added to the extract and heated for 1 h at
45 C, then quenched with methanol. The resulting mixture is dried
down, re-dissolved in 40% methanol and analysed by LC–APCI–MS/
MS using a reversed phase column (Betasil C18, 100  2.1 mm, 5 mm
particle size) with an acetonitrile/0.5% acetic acid/0.015% trichloro-
acetic acid gradient. [M + H]+ ions are formed in APCI which
fragment in MS/MS to [M + H-103]+ and to m/z 104 corresponding
to the loss of dimethylglycine and to protonated dimethylglycine,
respectively. Jiang et al. [77] have used this method for the analysis
of plasma from patients suffering from NPC1 disease. They used
MRM analysis to quantify 7-OC and 3b,5a,6b-triol from control
(n = 89), heterozygotes (n = 45) and homozygous NPC1 patients
(n = 109). For 7-OC they found remarkably large differences in the
three groups rising from 29 ng/mL in controls to 43.8 ng/mL in
heterozygotes to 229 ng/mL in NPC1 patients. 3b,5a,6b-Triol was
similarly increased in NPC1 patients. Although 7-OC can be formed
by ex vivo autoxidation of cholesterol and no attempt was made to
remove cholesterol during sample workup, the difference in[32]. (A) Upper panel, fraction A, with cholesterol oxidase. Lower panel, fraction B,
 7.37 min, 24S-HC; (C) 7.92 min, (25R) 26-HC; and (D) 10.15 min, 7a-HC plus 7a-HCO.
nisms suggested by Murphy [107] are shown in Supplementary Fig. S1.
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striking.
4.2.4. Derivatisation to oximes
A number of oxysterols posses a carbonyl group, e.g. 7a-HCO,
7a,12a-diHCO as does the acid 7aH,3O-CA. Carbonyl groups will
react with hydroxylamine-based reagents to give oximes. This
reaction has been exploited for decades in GC–MS and LC–MS
studies of oxosteroids [78]. Recently, DeBarber et al. have utilised
the O-(3-trimethylammonium-propyl) hydroxylamine reagent,
also called quaternary amonoxy (QAO) reagent, to derivatise
oxysterols possessing an oxo group [79,80] (Fig. 5F). They exploited
this method for the diagnosis of patients with CTX. CTX is a disease
resulting from sterol (25R)26-hydroxylase (CYP27A1) deﬁciency.
Derivatisation is simple; QAO reagent (210 mg) is added in
methanol containing 5% acetic acid to 4 mL of plasma or to a
dried blood spot, after 2 h at room temperature the mixture is
analysed by LC-ESI–MS/MS exploiting the MRM transition
[M]+! 152+. The likely structure of the ion at m/z 152 is shown
in Fig. 5F, based on fragmentation studies of other carbonyl
reactive reagents [81]. DeBarber et al. use a reversed phase column
(Luna C8, 50  2.1 mm, 5 mm particle size) and a water/acetonitrile/
0.1% formic acid gradient in a 6 min run. Sensitivity was 1 pg on-
column, and for 4 mL of plasma the lower limit of quantiﬁcationFig. 8. LC–MS(MSn) analysis using EADSA technology of a typical CTX patient plasma sam
B, without cholesterol oxidase. MS3 fragmentation, [M]+! [M-Py]+!, of peaks eluting at 
on an Orbitrap Elite. For comparison to normal plasma, levels of 24S-HC are similar in F
Fig. S2.(LLOQ) was 20 ng/mL. Using this methodology DeBarber et al.
found 7a,12a-diHCO to be diagnostic of CTX being elevated by a
factor of over 3000 in adults and by a factor of 10 in newborns.
4.2.5. Derivatisation to Girard hydrazones
Perhaps the most popular derivatisation method for LC–MS
analysis of oxysterols is derivatisation to Girard hydrazones [82].
This method has been extensively used by Roberg–Larsen and
Wilson in Norway [83–85], Shevchenko and colleagues in Germany
[86], DeBarber and co-workers in Canada [87,88], and Soroosh et al.
in the USA [89] and our own group in the UK
[29,30,32,33,51,52,90–96].
The Girard reagents have been used for decades in steroid
analysis [82]. They react with a carbonyl group of a steroid to give a
Girard hydrazone (Fig. 5G, step ii). Girard hydrazones are positively
charged on account of the presence of a quaternary amine group,
and give enhance steroid solubility in water, a property widely
exploited to aid steroid extraction from organic solvents [97]. The
charged nature of the Girard hydrazones makes them very suitable
for high sensitivity ESI–MS analysis [51,90,91,94,95,98]. Many
oxysterols have a 3b-hydroxy-5-ene group which can be treated
with cholesterol oxidase to give a 3-oxo-4-ene (Fig. 5G, step (i)
[99], suitable for subsequent Girard derivatisation. Once the 3-oxo-
4-ene group is in place derivatisation with the Girard reagents isple [32]. (A) Upper panel, fraction A, with cholesterol oxidase. Lower panel, fraction
(B) 9.55 min, 7b-HC; (C) 9.76 min, 7-OC; and (D) 10.14 min, 7a-HCO. Data generated
igs. 7 and 8. The MS3 spectrum of the peak eluting at 10.41 min, 6-HC, is shown in
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oxidised to 3-oxo compounds but the 3-oxo products react with
Girard reagents at a slower rate than the corresponding 3-oxo-4-
ene compounds [97]. There are two types of Girard reagent
generally employed; Girard T (GT) (2-hydrazinyl-2-oxoethyl)-
trimethylazanium chloride salt and Girard P (GP) 1-(hydrazino-
carbonylmethyl) pyridinium chloride or bromide salt. Our prefer-
ence is for the GP reagent, although most other groups use the GT
reagent. We have exploited enzymatic oxidation and GP deriva-
tisation, in a methodology we call enzyme-assisted derivatisation
for sterol analysis (EADSA) in the study of rodent brain, rodent and
human CSF and plasma/serum and also cells and medium (Table 1,
Table S1) [20,24,25,29,32,33,93–95].
Our preference is to extract oxysterols from tissue or ﬂuids into
ethanol to which isotope labelled standards are added, centrifuge,
and dilute the supernatant to 70% ethanol with water. The solution
is passed through a C18 solid phase extraction (SPE) column;
oxysterols and more polar sterols/steroids pass through the
column while cholesterol is retained. Oxysterols are then dried
and re-dissolved in propan-2-ol then treated with cholesterol
oxidase in KH2PO4 buffer. After 60 min at 37 C the reaction is
quenched with methanol and GP reagent added with acetic acid
catalyst. After overnight incubation at room temperature oxy-
sterols are separated from un-reacted reagent by a second SPE step,
this time using an Oasis HLB column. Oxysterols are eluted in
methanol.Fig. 9. LC–MS(MS3) analysis using EADSA technology of a typical SLOS patient plasma s
reconstructed ion chromatograms (RIC) targeted on hydroxy-8-dehydrocholesterol (2
fragmentation, [M]+! [M-Py]+!, of peaks eluting at (B) 7.07 min, 24H-8-DHC or 25H-8-
Elite. Proposed structures of fragment ions are shown in Fig. S3.Our current method of LC–MS analysis exploits reversed phase
LC on a Hypersil Gold C18 column (50  2.1 mm, 1.9 mm particle
size) with a methanol/acetonitrile/0.1% formic acid gradient and
detection with a ion trap-Orbitrap hybrid high resolution mass
spectrometer. Analyte identiﬁcation is achieved by using exact
mass, measured in the high resolution Orbitrap, and by multiple
stage fragmentation (MSn) in the ion trap. A signiﬁcant advantage
of GP derivatisation is that the derivatised oxysterols give distinct
fragmentation patterns (Fig. 5G) allowing isomer differentiation. A
further advantage is that the method is applicable to down-stream
metabolites of oxysterols including cholestenoic and cholenoic
acids. The website http://sterolanalysis.org.uk a useful resource
displaying MS3 spectra of GP derivatised sterols. The sensitivity of
the method allows oxysterols to be detected at the ng/mL level
from 100 mL of plasma and the 30 pg/mL level from 250 mL of CSF. It
is also applicable to vitamins D analysis [100].
Roberg-Larsen et al. [83,84] have adopted a similar approach
but using the GT reagent and exploiting a trap column, to remove
excess derivatisation reagent, prior to a miniaturised analytical
column (Ace C18, 150  1 mm or Ace C18 150  0.1 mm). They have
used both micro-LC and nano-LC to improve sensitivity. Using their
nano-LC-ESI–MS/MS method they were able to achieve fg
detection limits and proﬁle oxysterols in extracts of only 10,000
cells [84]. Ecdysteroids are polyhydroxylated sterols found in
insects, and Shevchenko and co-workers have exploited GT
derivatisation for the pg detection by LC-ESI–MS/MS of these
molecules [86].ample [32,101]. (A) Upper panel, fraction A, with cholesterol oxidase. Central panel,
4H-8-DHC, 25H-8-DHC, 26H-8-DHC). Lower panel, RIC targeted on 7,8-EC. MS3
DHC; (C) 7.65 min, 26H-8-DHC, (D) 9.95 min, 7,8-EC. Data generated on an Orbitrap
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A disadvantage of the EADSA strategy as outlined above is that
some oxysterols and cholestenoic acids naturally posses a 3-oxo-4-
ene function e.g. 7a-HCO, 7aH,3O-CA; this makes them indistin-
guishable from equivalent molecules oxidised with cholesterol
oxidase to contain this function i.e. 7a-HC, 3b,7a-diHCA. To solve
this conundrum we divide the oxysterol fraction eluting from the
ﬁrst SPE column into (A) and (B) fractions. The (A) fraction is
treated with cholesterol oxidase, while the (B) fraction is not. The
(B) fraction will give information about molecules with a natural
oxo group, the (A) fraction will give information about molecules
oxidised to contain a 3-oxo group and those naturally containing a
3-oxo group. Deconvolution of (B) from (A) reveals the quantity of
molecules oxidised to contain a 3-oxo group, i.e. those with a
natural 3b-hydroxy group. This procedure requires the recording of
two independent LC–MS runs with the obvious knock-on effects on
sample throughput. To streamline analysis we have introduced
isotope coded derivatisation reagents or quantitative charge-tags
[32].
The GP reagent is straight forward to synthesise as are isotope
labelled versions (Fig. 6A) [82]. For example, by reaction of [2H5]
pyridine with ethyl bromoacetate and then hydrazine, [2H5]GP is
synthesised [32]. In our EADSA methodology we now use [2H5]GPFig. 10. LC–MS(MSn) analysis of plasma from an infant suffering from oxysterol 7a-hy
hydroxycholesterol sulphates and, lower panel, dihydroxycholesterol sulphates. (B) RIC
glucuronides, and dihydroxycholesterol sulphate glucuronides, lower panel. (C) MS/MS s
ion-ESI on an Orbitrap Velos. (D) LC–MS analysis using EADSA technology of the infan
hydroxycholesterol glucuronides. Data generated by positive-ion ESI on the Orbitrap Xto derivatise (A) fractions and [2H0]GP to derivatise (B) fractions
and then combine the two fractions immediately before LC–MS.
Analytes in the (A) fraction are 5 Da heavier than their equivalents
in the (B) fraction so easily distinguishable in a single LC–MS run
(Fig. 6B). We now use the concept of differential mass tags in all our
analysis (Fig. 7). The GP skeleton is also applicable to developing
isobaric tags where two tags have the same nominal mass but
fragment in MS/MS to give ions of different m/z . These fragment
ions can then be used for relative quantiﬁcation of (A) and (B)
fractions (Fig. 6A and C). By generating a quadruplex it is possible
to analyse two samples as both (A) and (B) fractions in a single LC–
MS/MS run [32].
5. Applications of LC–MS for oxysterol analysis
5.1. Sterols in plasma from CTX patients
DeBarber et al. have used GP derivatisation without enzymatic
oxidation to identify and quantify sterols with a 3-oxo group in
plasma of CTX patients [87,88]. They scaled down the derivatisa-
tion method for 10 mL of plasma, omitting cholesterol removal and
enzymatic oxidation and removing excess reagent via an HPLC trap
column prior to the analytical column [88]. They developed both
LC-ESI–MS/MS with MRM and LC-ESI–MS with MS3 methods fordroxylase deﬁciency [32]. (A) RICs showing peaks corresponding to, upper panel,
s showing peaks corresponding to, upper panel, monohydroxycholesterol sulphate
pectrum of the peak eluting at 8.44 min. Data in (A)–(C) generated by LC-negative-
t plasma sample. Upper panel, RIC of hydroxycholesterol sulphates; lower panel
L. MS2 spectra of peaks eluting at 6.88 and 5.94 min are shown in Fig. S4.
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and LC-ESI–MS3 also for cholest-4,6-dien-3-one, 7a,12a-diHCO
and 7a,12a-dihydroxy-5b-cholestan-3-one. Each of these metab-
olites is greatly elevated in CTX plasma compared to healthy
individuals. We have found similar results when we have analysed
CTX plasma, but by including the cholesterol oxidase step we could
also show the almost complete absence of (25R)26-HC, 3b-HCA
and 3b,7a-diHCA from CTX plasma (Fig. 8) [32,93].
5.2. Unusual oxysterols in plasma
Some patients with CTX and all patients with Smith–Lemli–
Opitz syndrome (SLOS) have high levels of 7-DHC in plasma and
tissues [101]. SLOS results from 7-dehydrocholesterol reductase
(DHCR7) deﬁciency (see Fig. 3). Recently a new mechanism for the
formation of 7-OC was described where 7-DHC is oxidised by
CYP7A1 to 7-OC with cholesterol-7,8-epoxide (7,8-EC) as a side
product (Fig. 2C) [8]. Using EADSA to proﬁle plasma of SLOS
patients we are able to identify 7,8-EC and conﬁrm its absence in
plasma from control individuals (Fig. 9) [101]. Further proﬁling of
plasma from patients with SLOS allowed the identiﬁcation of
another unusual oxysterol, 26-hydroxy-8-dehydrocholesterol
(26H-8-DHC) ﬁrst reported in plasma by Wassif et al. [102],
presumably formed from 8-DHC in a CYP27A1 catalysed reaction
(Fig. 9) [Grifﬁths unpublished data]. Honda et al. [103] alsoFig. 11. LC–MS(MS3) analysis of typical human CSF using EADSA technology [95]. (A) U
cholesterol oxidase. MS3 fragmentation, [M]+! [M-Py]+!, of peaks eluting at (B) 2.04
diH,3O-CA. The MS3 spectrum of the peak eluting at 4.17 min is shown in Fig. S5. Dataidentiﬁed 26H-8-DHC in liver mitochondrial incubations from a rat
model of SLOS.
5.3. Oxysterol sulphates and glucuronides in plasma
At the beginning of this section we wrote that a limitation of
GC–MS was its inability to detect oxysterols conjugated with
glucuronic or sulphuric acids. In contrast, these oxysterols are
readily detected without derivatisation by LC-ESI–MS/MS when
operated in the negative ion mode [104]. This is illustrated by
analysis of plasma from an infant suffering from oxysterol 7a-
hydroxylase (CYP7B1) deﬁciency (Fig. 10) [12]. EADSA introduces
the GP group at position 3, so conjugates at this location are not
observed with the EADSA method. However, if sulphation or
glucuronidation is elsewhere the conjugated oxysterol can be
observed (Fig. 10). These modes of conjugation may be important
in different disease states.
5.4. Oxysterols in CSF
The levels of oxysterols in CSF are low, however, the
cholestenoic acids 3b-HCA, 3b,7a-diHCA and 7aH,3O-CA are far
higher (Table 1) [25,68,95]. Using our EADSA methodology we not
only identify these three acids in CSF, but also ﬁnd peaks
corresponding to down-stream acids (Fig. 11). In our earlierpper panel, fraction A, with cholesterol oxidase. Lower panel, fraction B, without
 min, 7a,24-diH,3O-CA; (C) 2.62 min, 7a,x-diH,3O-CA; and at (D) 3.53 min, 7a,25-
 generated on an Orbitrap Elite.
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and 3.53 min in the chromatograms shown in Fig. 11A to
correspond to 7a,24S-dihydroxy-3-oxocholest-4-en-26-oic
(7a,24-diH,3O-CA) and 7a,25-dihydroxy-3-oxocholest-4-en-26-
oic acids (7a,25-diH,3O-CA) [25,95]. Avanti Polar Lipids have
now synthesised these two molecules, and while identiﬁcation of
the peak eluting at 3.53 min as 7a,25-diH,3O-CA is correct, the
peak eluting at 2.62 min is not 7a,24-diH,3O-CA. In fact, 7a,24-
diH,3O-CA elutes a little earlier than the unknown peak, at
2.04 min. The MS3 spectrum of the peak eluting at 2.62 min suggest
that there is side-chain hydroxylation on the 7aH,3O-CA scaffold
presumably at C-22 or C-23. Remaining peaks in the chromato-
grams shown in Fig. 11A are compatible, according to retention
time and MS3 spectra, with 7a,12a-diH,3O-CA, however, an
authentic standard has yet to be synthesised. It should be noted
that 7a,25-diH,3O-CA and 7a,12a-diH,3O-CA appear as syn and
anti conformers, this is a consequence of derivatisation of an oxo
group, and can be seen as a disadvantage, i.e. dilution of ion signal,
or an advantage i.e. conﬁrmation of Girard derivatisation.
6. Internal standards, method validation and quality assurance
Although a number of publications for oxysterol analysis
describe validated methods [65,75], there are still questions about
accuracy of the various assays employed. A critical factor is the
purity of the standards used. Although a standard may be “pure”
according to TLC, GC–MS, LC–MS or NMR, there may be
contaminants which are not visible to the methods used, invalid-
ating the supposed molar concentration of the standard. In
collaboration with the Lipid Maps consortium Avanti Polar Lipids
Inc have produced a range of high quality quantitative standards of
deﬁned concentrations of oxysterols in deﬁned volumes of solvent
whose use should reduce inter laboratory variations [69]. Other
important factors for accurate quantiﬁcation that must be
considered are the isotopic purity of isotope labelled standards,
the use of appropriate standard curves generated under the same
conditions as for sample preparation and also the chromatographic
resolution of isomers.
To-date there have been two inter-laboratory surveys organised
by the European Network for Oxysterol Research (http://oxy-
sterols.com/) where serum samples have been distributed to
participating laboratories and oxysterol analysis made [105].
Twenty one laboratories participated in the second survey.
Unfortunately, ex vivo cholesterol autoxidation was found to be
a problem with highly variable concentrations of 7a-HC, 7b-HC
and 7-OC (% coefﬁcient of variation, %CV, 47–129%) returned. This
highlights the danger of using any of these metabolites for
diagnostic purposes. Even for side-chain oxysterols 24S-HC and
(25R)26-HC the %CV for different laboratories was about 60%.
Clearly more work is required to standardise analytical methods.
The reader is also reminded that a validated method is not
necessarily an accurate one and may not give the true answer.
7. Conclusions
To identify monogenetic disorders of cholesterol biosynthesis
and metabolism current LC–MS and GC–MS methods are
appropriate, for example CTX is readily diagnosed by an absence
or very low levels of (25R)26-HC and an elevation in 7a,12a-diHCO
in plasma, while oxysterol 7a-hydroxylase deﬁciency can be
diagnosed by high levels of both (25R)26-HC and 3b-HCA in
plasma. However, to compare plasma levels of 24S-HC from
patients with AD and controls, where the differences are likely to
be only small, methods with low CVs are required. This is
particularly relevant where data generated by multiplelaboratories is combined. Efforts to harmonise methodologies
are ongoing spearheaded by the European Network for Oxysterol
Research.
To-date most studies of oxysterols have adopted a targeted
approach; however, a non-targeted “lipidomic” approach has been
utilised by some. The idea of untargeted lipidomics is not new
[106], but faster and more sensitive instruments now make this
work-ﬂow readily available. It is perhaps this aspect of oxysterol
analysis where derivatisation strategies are most powerful. GC–MS
analysis of TMS ethers using electron ionisation provide spectra
rich in structural information allowing the determination of
unknown compounds. Similarly, GP derivatisation and LC–MS
exploiting MS3 gives structural information and the identiﬁcation
of unexpected oxysterols.
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